Search results for " Local"

showing 10 items of 2101 documents

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma

2021

Abstract Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and complete response (CR) rate in infused patients of 52% and 40%, respectively. We report outcomes with tisa‐cel in the standard‐of‐care (SOC) setting for R/R LBCL. Data from all patients with R/R LBCL who underwent leukapheresis from December 2018 until June 2020 with the intent to receive SOC tisa‐cel were retrospectively collected at 10 Spanish institutions. Toxicities were graded accor…

Male0301 basic medicine:aminoácidos péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores inmunológicos::receptores de antígenos::receptores de antígenos de linfocitos T [COMPUESTOS QUÍMICOS Y DROGAS]Cancer Researchnon‐Hodgkin's lymphomaBest Overall Responsehematological cancer:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Non- Hodgkin's lymphomaGastroenterology0302 clinical medicineMedicine research:Other subheadings::/therapeutic use [Other subheadings]CàncerB-cell lymphomaRC254-282CancerOriginal ResearchReceptors Chimeric AntigenNeoplasms. Tumors. Oncology. Including cancer and carcinogensnon&#8208Standard of CareMiddle AgedPatologiaHodgkin&aposProgression-Free SurvivalCytokine release syndromeclinical cancer researchOncology:neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso [ENFERMEDADES]030220 oncology & carcinogenesisCytokinesFemaleLymphoma Large B-Cell Diffusenon-Hodgkin's lymphomamedicine.medical_specialtyReceptors Antigen T-CellCèl·lules B - Tumors - Tractament:Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]Investigació mèdicaReal world evidence03 medical and health sciencess lymphoma:Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma Non-Hodgkin::Lymphoma B-Cell::Lymphoma Large B-Cell Diffuse [DISEASES]Refractoryclinical observationsInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingLeukapheresis:Amino Acids Peptides and Proteins::Proteins::Membrane Proteins::Receptors Cell Surface::Receptors Immunologic::Receptors Antigen::Receptors Antigen T-Cell [CHEMICALS AND DRUGS]AgedRetrospective Studies:Otros calificadores::/uso terapéutico [Otros calificadores]business.industryTeràpia cel·lularClinical Cancer ResearchLeukapheresismedicine.diseaseMalaltia de HodgkinNon-Hodgkin's lymphomaLymphoma030104 developmental biologyHodgkin's diseaseNeoplasm Recurrence LocalbusinessCancer Medicine
researchProduct

Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis

2017

AbstractThe extranodal extension (ENE) of nodal metastasis involves the extension of neoplastic cells through the lymph node capsule into the perinodal adipose tissue. This morphological feature has recently been indicated as an important prognostic factor in various cancer types, but its role in prostate cancer is still unclear. We aimed to clarify it, performing the first meta-analysis on this issue, comparing prognostic parameters in surgically treated, node-positive prostate cancer patients with (ENE+) vs. without (ENE−) ENE. Data were summarized using risk ratios (RRs) for number of deaths/recurrences and hazard ratios (HRs), with 95% confidence intervals (CI), for the time-dependent r…

Male0301 basic medicineBiochemical recurrenceOncologymedicine.medical_specialtyPathologyScienceprostate cancer he extranodal extension (ENE) perinodal adipose tissuenot knownArticle03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineJournal ArticleOdds RatioHumansMedicineperinodal adipose tissueNeoplasms Adipose TissueAgedProportional Hazards ModelsMultidisciplinarybusiness.industryProportional hazards modelQHazard ratioRProstateProstatic NeoplasmsCancerOdds ratioMiddle Agedprostate cancerPrognosismedicine.disease3. Good health030104 developmental biologyLymphatic Metastasis030220 oncology & carcinogenesisRelative riskhe extranodal extension (ENE)MedicineProstate surgeryLymph NodesNeoplasm Recurrence LocalbusinessScientific Reports
researchProduct

Genome-wide identification of runs of homozygosity islands and associated genes in local dairy cattle breeds

2018

Runs of homozygosity (ROH) are widely used as predictors of whole-genome inbreeding levels in cattle. They identify regions that have an unfavorable effect on a phenotype when homozygous, but also identify the genes associated with traits of economic interest present in these regions. Here, the distribution of ROH islands and enriched genes within these regions in four dairy cattle breeds were investigated. Cinisara (71), Modicana (72), Reggiana (168) and Italian Holstein (96) individuals were genotyped using the 50K v2 Illumina BeadChip. The genomic regions most commonly associated with ROHs were identified by selecting the top 1% of the single nucleotide polymorphisms (SNPs) most commonly…

Male0301 basic medicineCandidate generuns of homozygosity islandGenotypeRuns of homozygosity islands genomic regions candidate genes local dairy cattle bovine beadchip 50KLocus (genetics)Single-nucleotide polymorphismBiologyRuns of HomozygosityPolymorphism Single NucleotideGenomeSF1-1100bovine beadchip 50K; candidate genes; genomic regions; local dairy cattle; runs of homozygosity islands; Animal Science and ZoologySettore AGR/17 - Zootecnica Generale E Miglioramento Genetico03 medical and health sciencesAnimalsInbreedinggenomic regionsGeneDairy cattleGeneticslocal dairy cattleGenomeReproductionHomozygote0402 animal and dairy sciencecandidate gene04 agricultural and veterinary sciences040201 dairy & animal sciencegenomic regionAnimal cultureruns of homozygosity islandsDairyingPhenotype030104 developmental biologybovine beadchip 50KCattleFemaleAnimal Science and Zoologycandidate genesInbreeding
researchProduct

Comprehensive Genomic and Transcriptomic Analysis of Three Synchronous Primary Tumours and a Recurrence from a Head and Neck Cancer Patient

2021

Synchronous primary malignancies occur in a small proportion of head and neck squamous cell carcinoma (HNSCC) patients. Here, we analysed three synchronous primaries and a recurrence from one patient by comparing the genomic and transcriptomic profiles among the tumour samples and determining the recurrence origin. We found remarkable levels of heterogeneity among the primary tumours, and through the patterns of shared mutations, we traced the origin of the recurrence. Interestingly, the patient carried germline variants that might have predisposed him to carcinogenesis, together with a history of alcohol and tobacco consumption. The mutational signature analysis confirmed the impact of alc…

Male0301 basic medicineOncologyAlcohol exposuremedicine.disease_causeGermlineNeoplasms Multiple PrimaryTranscriptomeFatal Outcome0302 clinical medicineMedicineBiology (General)Immune cell infiltrationSpectroscopysynchronous multiple primary malignanciesSmokersimmune cell infiltrationGenomicsGeneral MedicineComputer Science Applicationswhole exome sequencing (WES)Chemistrysomatic single nucleotide variantsHead and Neck Neoplasms030220 oncology & carcinogenesismedicine.medical_specialtyrecurrent head and neck squamous cell carcinoma (HNSCC)Alcohol DrinkingQH301-705.5ArticleCatalysisInorganic Chemistry03 medical and health sciencesInternal medicineHumansPhysical and Theoretical ChemistryQD1-999Molecular BiologyAgedNeoplasm Stagingbusiness.industryGene Expression ProfilingOrganic ChemistryHead and neck cancerRNA sequencing (RNA-seq)medicine.diseaseHead and neck squamous-cell carcinoma030104 developmental biologygermline variantsMutationClinical valueNeoplasm Recurrence LocalbusinessCarcinogenesisInternational Journal of Molecular Sciences
researchProduct

EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer

2018

Epidermal growth factor receptor (EGFR) gene copy number (GCN) increase is associated with a favorable anti-EGFR antibody treatment response in RAS wild-type metastatic colorectal cancer. However, there are limited and comparative data regarding the EGFR GCN in primary colorectal cancer tumors and corresponding metastases or the effect of anti-EGFR antibody treatment on EGFR GCN in recurrent disease. In addition, little is known about the potential EGFR GCN changes during anti-EGFR therapy in comparison with other treatment regimens. EGFR GCN was analyzed by EGFR immunohistochemistry-guided silver in situ hybridization in primary and corresponding recurrent local or metastatic tumors from 8…

Male0301 basic medicineTime FactorsColorectal cancerBLOCKADEGene DosageCetuximabmedicine.disease_causeAntineoplastic Agents Immunological0302 clinical medicinePREDICTS RESPONSEMedicineHETEROGENEITYBENEFITCopy-number variationEpidermal growth factor receptorIn Situ Hybridization FluorescenceAged 80 and overbiologyPanitumumabvasta-aineetMiddle AgedImmunohistochemistry3. Good healthErbB ReceptorsGene Expression Regulation NeoplasticTreatment OutcomeRAS MUTATIONSChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleKRASAntibodyColorectal NeoplasmsAdultgene copy numbermedicine.drug_classCETUXIMAB THERAPY3122 Cancerssilver in situ hybridizationDown-Regulationcolorectal cancerIn situ hybridizationAdenocarcinomaMonoclonal antibodyta3111Pathology and Forensic MedicineProto-Oncogene Proteins p21(ras)03 medical and health sciencesKRASHumansWILD-TYPEMETAANALYSISAgedRetrospective Studiessyöpähoidotbusiness.industrymedicine.diseaseta3122Blockadeperäsuolisyöpä030104 developmental biologymonoclonal antibodyMutationCancer researchbiology.protein3111 BiomedicineNeoplasm Recurrence Localbusinessepidermal growth factor receptorACQUIRED-RESISTANCEHuman Pathology
researchProduct

Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

2019

Background & Aims: The effectiveness of direct-acting antivirals (DAAs) against hepatitis C virus (HCV), following successful treatment of early hepatocellular carcinoma (HCC), has been studied extensively. However, the benefit in terms of overall survival (OS) remains to be conclusively demonstrated. The aim of this study was to assess the impact of DAAs on OS, HCC recurrence, and hepatic decompensation. Methods: We prospectively enrolled 163 consecutive patients with HCV-related cirrhosis and a first diagnosis of early Barcelona Clinic Liver Cancer stage 0/A HCC, who had achieved a complete radiologic response after curative resection or ablation and were subsequently treated with DAA…

Male0301 basic medicinemedicine.medical_specialtySurvival rateCarcinoma HepatocellularCirrhosisSustained Virologic ResponsePrognosiHepatitis C virus (HCV) Hepatocellular carcinoma (HCC) Direct-acting antiviral (DAA) Overall survival Prognosis Survival rate Liver cirrhosisHepacivirusAntiviral AgentsGastroenterologyLiver cirrhosi03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansEarly Hepatocellular CarcinomaOverall survivalProspective StudiesHepatocellular carcinoma (HCC)Propensity ScoreSurvival rateAgedAged 80 and overHepatologybusiness.industryLiver NeoplasmsHazard ratioDirect-acting antiviral (DAA)Hepatitis CHepatitis C virus (HCV)Middle Agedmedicine.diseasePrognosisHepatitis CDirect-acting antiviral (DAA); Hepatitis C virus (HCV); Hepatocellular carcinoma (HCC); Liver cirrhosis; Overall survival; Prognosis; Survival rate030104 developmental biologyHepatocellular carcinomaLiver cirrhosisFemale030211 gastroenterology & hepatologyNeoplasm Recurrence LocalLiver cancerbusinessViral hepatitisFollow-Up Studies
researchProduct

Hearing in Real-Life Environments (HERE) : Structure and Reliability of a Questionnaire on Perceived Hearing for Older Adults

2019

Supplemental Digital Content is available in the text.

MaleAgingIntraclass correlationHealth StatusvanhuksetAudiologyIntelligibility (communication)01 natural sciencesspeech perception0302 clinical medicineHearingSurveys and Questionnaires030223 otorhinolaryngology010301 acousticshuonokuuloisuusAged 80 and overSpeech perceptionikäkuulota3142Social ParticipationkuuloHearing levelTest scoreComputingMethodologies_DOCUMENTANDTEXTPROCESSINGAuditory PerceptionFemalemedicine.symptomPsychologyikääntyneetResearch Articlemedicine.medical_specialtySpeech perceptionHearing loss03 medical and health sciencesSpeech and HearingCronbach's alpha0103 physical sciencesmedicineotorhinolaryngologic diseasesHumansSound LocalizationHearing Lossquestionnaire validationOrientation SpatialAgedagingReproducibility of ResultsQuestionnaire validationta3125ikääntyminenOtorhinolaryngologyhearingStandardized coefficientQuality of LifeSelf ReportFactor Analysis StatisticalCOSMIN criteria
researchProduct

Oscillatory Dynamics Underlying Perceptual Narrowing of Native Phoneme Mapping from 6 to 12 Months of Age

2016

During the first months of life, human infants process phonemic elements from all languages similarly. However, by 12 months of age, as language-specific phonemic maps are established, infants respond preferentially to their native language. This process, known as perceptual narrowing, supports neural representation and thus efficient processing of the distinctive phonemes within the sound environment. Although oscillatory mechanisms underlying processing of native and non-native phonemic contrasts were recently delineated in 6-month-old infants, the maturational trajectory of these mechanisms remained unclear. A group of typically developing infants born into monolingual English families, …

MaleAgingmedicine.medical_specialtysource localizationSpeech perceptionFirst languageperceptual narrowingAudiologyAuditory cortexSemanticsLanguage Development050105 experimental psychologyDevelopmental psychology03 medical and health sciencesvärähtelyt0302 clinical medicineBiological ClocksGamma RhythmmedicinePerceptual narrowingGamma RhythmHumans0501 psychology and cognitive sciencesTheta RhythmResearch ArticlesLanguageAuditory Cortextime-frequency analysesinfantsGeneral Neuroscience05 social sciencesInfantSemanticsphonemic mappingLanguage developmentEvoked Potentials AuditorySpeech PerceptionFemaleSyllablePsychology030217 neurology & neurosurgeryThe Journal of Neuroscience
researchProduct

Efficacy of Periportal Infiltration and Intraperitoneal Instillation of Ropivacaine After Laparoscopic Surgery in Children

2009

Postoperative pain is less intense after laparoscopic than after open surgery. However, minimally invasive surgery is not a a pain-free procedure. Many trials have been done in adults using intraperitoneal and/or incisional local anesthetic, but similar studies have not yet been reported in the literature in children. Aim: The aim of this study was to evaluate the analgesic effect of periportal infiltration and intraperitoneal instillation of ropivacaine in children undergoing laparoscopic surgery. Materials and Methods: Thirty patients who underwent laparoscopic surgery were randomly allocated to one of three groups. Group A (n 10) received local infiltration of port sites with 10 mL of ro…

MaleAnalgesic effectLaparoscopic surgerymedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentAnalgesicBody Mass Indexlaw.inventionRandomized controlled triallawmedicineHumansInfusions ParenteralRopivacaineAnesthetics LocalChildPain MeasurementPain Postoperativebusiness.industryLocal anestheticRopivacaineOpen surgerySettore MED/20 - Chirurgia Pediatrica E Infantilelaparoscopic surgery periportal infiltrationmedicine.diseaseAmidesSurgeryInstillation DrugTreatment OutcomeAnesthesiaFemaleLaparoscopySurgerybusinessInfiltration (medical)medicine.drugJournal of Laparoendoscopic & Advanced Surgical Techniques
researchProduct

Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder: Phase I-II study on marker lesions

2004

Abstract Objectives To study the ablative activity of intravesical gemcitabine against superficial transitional cell carcinoma of the bladder at different doses and concentrations. Methods A total of 27 patients were treated with intravesical gemcitabine after transurethral resection during which one to three papillary marker lesions were left unresected. Starting 14 days after transurethral resection, six instillations of gemcitabine were given at weekly intervals. Gemcitabine, diluted in 50 mL of saline solution and maintained for 2 hours, was given at the dose of 500 mg, 1000 mg, and 2000 mg in groups of 9 patients each. A complete response (CR) was defined as negative cytology, cystosco…

MaleAntimetabolites Antineoplasticmedicine.medical_specialtyUrologyUrinary systemUrologySalvage therapyDeoxycytidineDisease-Free SurvivalSettore MED/24 - UrologiamedicineCarcinomaHumansProdrugsAgedSalvage TherapyCarcinoma Transitional CellUrinary bladderDose-Response Relationship Drugmedicine.diagnostic_testbusiness.industryRemission InductionCystoscopyMiddle Agedmedicine.diseaseGemcitabineGemcitabineGemcitabineSurgeryAdministration IntravesicalTreatment Outcomemedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsTolerabilityFemaleNeoplasm Recurrence LocalbusinessFollow-Up Studiesmedicine.drug
researchProduct